• Publications
  • Influence
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
A role for EMT in the blood-borne dissemination of human breast cancer is supported as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)–β pathway components and the FOXC1 transcription factor.
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon
Observations point to a potential oncogenic role for YAP in 11q22-amplified human cancers, and suggest that this highly conserved signaling pathway identified in Drosophila regulates both cellular proliferation and apoptosis in mammalian epithelial cells.
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.
It is demonstrated that hypoxia and REDD1 suppress mammalian TORC1 (mTORC1) activity by releasing TSC2 from its growth factor-induced association with inhibitory 14-3-3 proteins, which defines a molecular mechanism of signal integration by TSC1/2 that provides insight into the ability of REDD 1 to function in a hypoxIA-dependent tumor suppressor pathway.
Gene expression profiles of human breast cancer progression
The combined use of laser capture microdissection and DNA microarrays generate in situ gene expression profiles of the premalignant, preinvasive, and invasive stages of human breast cancer, revealing extensive similarities at the transcriptome level among the distinct stages of progression.
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
  • D. Bell, T. Lynch, D. Haber
  • Biology, Medicine
    Journal of clinical oncology : official journal…
  • 1 November 2005
EGFR mutations and, to a lesser extent, amplification appear to identify distinct subsets of NSCLC with an increased response to gefitinib, and the combination of gefithinib with chemotherapy does not improve survival in patients with these molecular markers.
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
A neoadjuvant trial of cisplatin in TNBC explored specific biomarkers to identify predictors of response and found decreased BRCA1 expression may identify subsets of TNBCs that are cis platin sensitive.